Molecular Therapeutics Theme 2 Accomplishments

Theme 2: Identify cellular/molecular determinants and clinically relevant biomarkers of treatment response on which to base therapy

Scientific Accomplishments 

Drs. Bepler, Gadgeel, A Schwartz, and Cote, working with Dr. Bollig-Fischer, identified “driver” mutations in non-small cell lung cancer (NSCLC) in African American and European American patients using the Sequenom MassArray system and a multiplexed panel for 214 oncogenic mutations in 26 genes previously identified in NSCLC. African Americans with NSCLC exhibited multiple genetic mutations more frequently than European Americans with a different mutation profile. These results provided impetus for CAP/CLIA certification of the Genomics Core in 2013 for use of custom panels for lung cancer oncogenes and amplifications/deletions.

  • Lead researchers - Drs. Bepler, Gadgeel, and Bollig-Fischer
  • Collaborative researchers - Drs. Schwartz and Cote

Dr. Ratnam, working with Drs. Gadgeel, Shields, Matherly, and Bepler, demonstrated the role of glucocorticoid receptor (GR) status as a determinant of the variability in the sensitivity of non-small cell lung cancer (NSCLC) cells to pemetrexed (PEM), a S-phase-targeted drug in front-line or maintenance therapy  of advanced NSCLC, generally administered with dexamethasone (Dex). Their results predict that in non-squamous NSCLC, S-phase suppression by Dex, combined with a reduction in PEM transport, attenuates responsiveness to PEM and that GR status is an important determinant of tumor variability of this response.  Based on these in vitro results, an investigator-initiated clinical trial (Shields, Lead PI; Ratnam, Gadgeel, Heilbrun, collaborators) is enrolling NSCLC patients who will be screened by RT-PCR for high levels of GRα, then imaged with FLT-PET to test the hypothesis that Dex will decrease S-phase progression, as reflected in decreased activity of thymidine kinase-1.

  • Lead researchers - Drs. Ratnam. Gadgeel, Shields, Matherly and Bepler.
  • Collaborative researcher - Dr. Heilbrun

The Latest From Karmanos Cancer Institute

News

Free Fitness Classes Now Available for Female Cancer Survivors and Those At-risk in Dearborn Heights

Click here to read in Arabic. The Barbara Ann Karmanos Cancer Institute is partnering with Wayne State University (WSU) School of Medicine and HYP...

Read More

Karmanos, McLaren’s 12th Pink Out the Park with Detroit Tigers Inspires Sea of Pink at Comerica Park

The Annual Pink Out the Park, a partnership between the Barbara Ann Karmanos Cancer Institute , the Detroit Tigers and McLaren Health Care, the of...

Read More

Every Step of the Way: Support Resources for Our Cancer Survivors

June is recognized yearly as National Cancer Survivors Month, an important time to recognize the strength and perseverance of cancer survivors wor...

Read More
News

97.1 The Ticket | Pink Out the Park

Listen Now

WWJ | Genetic Counselor Available to Speak with at Screening Saves Lives Event on June 8

Listen Now

WWJ | Screening Saves Lives Event Gives Participants Opportunity to Talk to Genetic Counselor

Listen Now